Medexus Financial Statements From 2010 to 2025

MDP Stock   2.70  0.05  1.89%   
Medexus Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Medexus Pharmaceuticals' valuation are provided below:
Gross Profit
63.5 M
Profit Margin
0.0207
Market Capitalization
87.1 M
Enterprise Value Revenue
0.7128
Revenue
108.3 M
We have found one hundred twenty available fundamental ratios for Medexus Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Medexus Pharmaceuticals' last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 24th of July 2025, Market Cap is likely to drop to about 41.2 M. In addition to that, Enterprise Value is likely to drop to about 53.8 M

Medexus Pharmaceuticals Total Revenue

113.75 Million

Check Medexus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medexus Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 45.3 M, Other Operating Expenses of 121.1 M or Operating Income of 8.6 M, as well as many indicators such as Price To Sales Ratio of 1.63, Dividend Yield of 0.0 or Days Sales Outstanding of 55.26. Medexus financial statements analysis is a perfect complement when working with Medexus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Medexus Pharmaceuticals Technical models . Check out the analysis of Medexus Pharmaceuticals Correlation against competitors.

Medexus Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets180.4 M171.8 M75.1 M
Slightly volatile
Total Current Liabilities102.2 M97.3 M30.5 M
Slightly volatile
Total Stockholder Equity54.8 M52.1 M16.6 M
Slightly volatile
Cash25.2 M24 M9.1 M
Slightly volatile
Cash And Short Term Investments25.2 M24 M9.1 M
Slightly volatile
Common Stock Shares Outstanding17.9 M32.3 M15.3 M
Pretty Stable
Liabilities And Stockholders Equity180.4 M171.8 M75.1 M
Slightly volatile
Total Liabilities63.6 M119.7 M54.6 M
Slightly volatile
Total Current Assets84.6 M80.6 M32.7 M
Slightly volatile
Short and Long Term Debt Total28.8 M57.4 M23.4 M
Slightly volatile
Other Current Liabilities118.8 K125 K3.1 M
Pretty Stable
Property Plant And Equipment Net574.1 K689 K431.5 K
Slightly volatile
Current Deferred Revenue48.3 M46 M12.5 M
Slightly volatile
Accounts Payable6.5 M5.7 M4.6 M
Slightly volatile
Non Current Assets Total53.4 M91.3 M39.9 M
Slightly volatile
Net Receivables10.7 M13.2 M8.1 M
Slightly volatile
Non Current Liabilities Total38.9 M22.4 M28.9 M
Slightly volatile
Inventory37.1 M35.3 M11.6 M
Slightly volatile
Other Current Assets357.2 K376 K728.2 K
Slightly volatile
Intangible Assets43.7 M71.6 M32.7 M
Slightly volatile
Other Assets9.4 MM2.3 M
Slightly volatile
Non Currrent Assets Other11.1 M10.6 M2.9 M
Slightly volatile
Common Stock58.6 M96.1 M43.5 M
Slightly volatile
Long Term Debt188.1 K198 K13 M
Slightly volatile
Long Term Debt Total188.1 K198 K13 M
Slightly volatile
Capital Surpluse9.5 M12 M6.5 M
Slightly volatile
Cash And Equivalents12.7 M24 M8.2 M
Slightly volatile
Property Plant Equipment780.4 K689 K454.2 K
Slightly volatile
Net Invested Capital70.3 M89.3 M38.8 M
Slightly volatile
Short and Long Term Debt20.6 M37 M10.1 M
Slightly volatile
Other Liabilities30.9 M25.2 M37 M
Slightly volatile
Good Will10.8 M10 M8.5 M
Slightly volatile
Accumulated Other Comprehensive Income4.6 M7.1 M2.8 M
Slightly volatile
Capital Stock73.1 M96.1 M56.9 M
Slightly volatile
Property Plant And Equipment Gross2.1 MM1.8 M
Slightly volatile

Medexus Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative45.3 M43.2 M14.6 M
Slightly volatile
Other Operating Expenses121.1 M115.3 M45 M
Slightly volatile
Total Operating Expenses101.2 M96.4 M29 M
Slightly volatile
Selling And Marketing Expenses9.3 M12.2 M8.1 M
Slightly volatile
Total Revenue113.7 M108.3 M44.3 M
Slightly volatile
Gross Profit28.9 M56.6 M22.1 M
Slightly volatile
Research Development4.5 M8.3 M2.9 M
Slightly volatile
Depreciation And Amortization9.5 MM3.7 M
Slightly volatile
Interest Expense6.9 M8.2 M4.8 M
Slightly volatile
Cost Of Revenue29.7 M51.7 M19 M
Slightly volatile
Reconciled Depreciation5.1 M7.2 M2.7 M
Slightly volatile

Medexus Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.5 M5.3 M6.4 M
Slightly volatile
End Period Cash Flow25.2 M24 M9.1 M
Slightly volatile
Stock Based Compensation767 K411 K626.3 K
Slightly volatile
Depreciation240.3 K253 K1.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.630.400830.3233
Slightly volatile
Days Sales Outstanding55.2644.831564.8017
Slightly volatile
Average Payables7.9 M11.3 M6.1 M
Slightly volatile
Stock Based Compensation To Revenue0.03780.00380.0839
Slightly volatile
Capex To Depreciation0.360.37983.0854
Slightly volatile
EV To Sales1.410.522729.9155
Slightly volatile
Inventory Turnover1.41.46641.451
Slightly volatile
Days Of Inventory On Hand331249513
Slightly volatile
Payables Turnover9.489.03113.1422
Slightly volatile
Sales General And Administrative To Revenue0.05970.26170.387
Slightly volatile
Research And Ddevelopement To Revenue0.140.07620.1648
Slightly volatile
Capex To Revenue0.02390.02520.1172
Slightly volatile
Cash Per Share0.990.92840.9599
Very volatile
Days Payables Outstanding38.440.4161788
Slightly volatile
Intangibles To Total Assets0.330.47490.3404
Slightly volatile
Current Ratio60.90.82810.7229
Very volatile
Receivables Turnover6.868.14166.456
Slightly volatile
Graham Number1.31.791.3275
Slightly volatile
Debt To Equity0.680.7131.4559
Slightly volatile
Capex Per Share0.110.10560.1123
Slightly volatile
Average Receivables25.4 M24.2 M9.9 M
Slightly volatile
Revenue Per Share4.64.19542.6766
Slightly volatile
Interest Debt Per Share1.771.75721.7657
Slightly volatile
Debt To Assets0.420.21640.3148
Slightly volatile
Operating Cycle407294579
Slightly volatile
Days Of Payables Outstanding38.440.4161788
Slightly volatile
Long Term Debt To Capitalization0.00360.00380.375
Slightly volatile
Total Debt To Capitalization0.460.41620.4582
Slightly volatile
Debt Equity Ratio0.680.7131.4559
Slightly volatile
Quick Ratio60.90.465310.3562
Very volatile
Cash Ratio31.010.24646.1783
Pretty Stable
Days Of Inventory Outstanding331249513
Slightly volatile
Days Of Sales Outstanding55.2644.831564.8017
Slightly volatile
Fixed Asset Turnover158157143
Very volatile
Debt Ratio0.420.21640.3148
Slightly volatile
Price Sales Ratio1.630.400830.3233
Slightly volatile
Asset Turnover1.460.63040.6587
Pretty Stable
Gross Profit Margin0.640.52230.6549
Slightly volatile

Medexus Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap41.2 M43.4 M151.3 M
Slightly volatile
Enterprise Value53.8 M56.6 M167.2 M
Slightly volatile

Medexus Fundamental Market Drivers

Forward Price Earnings15.361
Cash And Short Term Investments24 M

About Medexus Pharmaceuticals Financial Statements

Medexus Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Medexus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue46 M48.3 M
Total Revenue108.3 M113.7 M
Cost Of Revenue51.7 M29.7 M
Stock Based Compensation To Revenue 0.00  0.04 
Sales General And Administrative To Revenue 0.26  0.06 
Research And Ddevelopement To Revenue 0.08  0.14 
Capex To Revenue 0.03  0.02 
Revenue Per Share 4.20  4.60 
Ebit Per Revenue 0.08 (0.06)

Pair Trading with Medexus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Medexus Stock

  0.73GOLD GoldMiningPairCorr
  0.54BRY Bri Chem CorpPairCorr
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medexus Stock

Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.